Last year, President Joe Biden tasked HHS with developing a national action plan to combat long COVID, a complex, multisymptomatic disease that appears months after a COVID-19 infection and leaves many of its patients unable to work.
MODERNA SAYS ITS RNA VACCINE WAS NEARLY 84% EFFECTIVE AT PREVENTING SYMPTOMS IN ADULTS 60 AND OLDER
“The Biden-Harris administration is supporting patients, physicians, and caregivers by providing science-based best practices for treating long COVID, maintaining insurance coverage, and protecting the rights of painters when they return to work while facing uncertainties. of his illness. ” HHS Secretary Xavier Becerra said.
The investment will be used to increase face-to-face and virtual visits, identify new satellite clinics and an educational initiative to generate referrals. Limited wisdom and acceptance among clinicians contributed to delays in diagnoses and referrals.
Medical treatment of a coronavirus patient in the intensive care unit of the Cleveland Clinic in Cleveland, Ohio, on Jan. 7, 2022. (REUTERS/Shannon Stapleton/File Photo)
The cash will also be spent on social services, hiring interpreters, patient organisation systems and behavioural skills support. The grants prioritize underserved, rural, vulnerable, and minority populations who are disproportionately impacted by long COVID.
The disease affects about 7 percent of all American adults and 2. 3 percent of the world’s population and has claimed about $386 billion in lost wages, savings and medical bills, according to an April study by the nonprofit Solve Long Covid Initiative. Research and Promotion Group.
CLICK HERE FOR THE FOX NEWS APP
More than two hundred symptoms have been linked to the syndrome, adding excessive fatigue, difficulty thinking, headaches, dizziness when standing, sleep problems, chest pain, blood clots, immune dysregulation and even diabetes.
No proven remedy is yet available, studies are still being conducted. The National Institutes of Health (NIH) is leading a $1. 15 billion effort, the RECOVER program, which introduced two clinical trials in July that will compare at least four potential remedies.